AstraZeneca Shares Rise as Cost-Cutting Plans Draw Investor Credit
AJ Bell's Russ Mould says investors are rewarding AstraZeneca's plans for major cost cuts to free up cash for investment. The excerpt says shares rose but gives no magnitude.
AJ Bell's Russ Mould says investors are rewarding AstraZeneca's plans for major cost cuts to free up cash for investment. The excerpt says shares rose but gives no magnitude.